person

Shahram A.

Country
France
Department
Centre de référence des Maladies Neuromusculaires rares et de la SLA

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
168
Sites with multiple studies

Has run more than one trial at 168 of 295 partner sites.

Specializations

Neuromuscular Disorders

This investigator specializes in treating various forms of myasthenia gravis, including both AChR antibody positive and seronegative variants, as well as congenital myasthenic syndrome. Their work extends to muscular conditions like Becker muscular dystrophy and myotonic dystrophy type 1.

  • Generalized Myasthenia Gravis
  • Muscular Dystrophies
  • Congenital Neuromuscular Disorders

Inflammatory Neuropathies

The investigator focuses on treating chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy. Their expertise includes managing anti-MAG neuropathy and implementing innovative therapeutic approaches for treatment-resistant cases.

  • Autoimmune Neuropathies
  • Demyelinating Conditions
  • Motor Neuropathies

Inflammatory Myopathies

Research interests encompass various inflammatory muscle conditions, including dermatomyositis and inclusion body myositis. The investigator explores both conventional and experimental therapeutic approaches for these challenging conditions.

  • Inflammatory Muscle Diseases
  • Autoimmune Myopathies
  • Progressive Muscle Disorders

Neurodegenerative Disorders

The investigator has significant involvement in treating amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth disease. Their work includes research on metabolic conditions like Pompe disease.

  • Motor Neuron Disease
  • Hereditary Neuropathies
  • Metabolic Muscle Disorders

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.